CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands		Total		8.25% Convertible Notes	Common stock issued under Tumim Purchase Agreements	Common stock issued under Equity Distribution Agreement, net	Direct Offering	Public Offering	Common Stock		Common Stock 8.25% Convertible Notes		Common Stock Common stock issued under Tumim Purchase Agreements	Common Stock Common stock issued under Equity Distribution Agreement, net		Common Stock Direct Offering		Common Stock Public Offering	Additional Paid-in Capital	Additional Paid-in Capital 8.25% Convertible Notes	Additional Paid-in Capital Common stock issued under Tumim Purchase Agreements	Additional Paid-in Capital Common stock issued under Equity Distribution Agreement, net	Additional Paid-in Capital Direct Offering	Additional Paid-in Capital Public Offering	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2022	[1]								17,097,850
Balance at beginning of period at Dec. 31, 2022		$ 526,479							$ 2	[1]									$ 2,562,904						$ (2,034,850)	$ (1,577)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		224,121							224,121	[1]
Exercise of stock options		$ 7,155																	7,155
Issuance of shares for RSU awards (in shares)	[1]								441,585
Common stock issued (in shares)	[1]												1,073,726	2,278,375		1,979,167		5,441,468
Common stock issued					$ 67,587	$ 117,525	$ 63,156	$ 127,893								$ 1	[1]				$ 67,587	$ 117,525	$ 63,155	$ 127,893
Common stock issued for conversions of convertible notes (in shares)	[1]										16,486,475
Common stock issued for conversions of convertible notes				$ 526,943							$ 1	[1]								$ 526,942
Common stock received for contingent stock consideration (in shares)	[1]								(686,667)
Common stock received for contingent stock consideration		(69,939)																	(2)						(69,937)
Reclassification of conversion features embedded in Toggle Convertible Notes to equity		241,851																	241,851
Reclassification of share-based payment awards from liability to equity		20,992																	20,992
Reclassification of share-based payment awards from equity to liability		(10,401)																	(10,401)
Stock-based compensation		64,800																	64,800
Net loss		(966,282)																							(966,282)
Other comprehensive income		$ 1,415																								1,415
Balance at end of period (in shares) at Dec. 31, 2023		44,336,100	[2]						44,336,100	[1]
Balance at end of period at Dec. 31, 2023		$ 719,174							$ 4	[1]									3,790,401						(3,071,069)	(162)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		0
Issuance of shares for RSU awards (in shares)	[1]								469,726
Issuance of shares for RSU awards		$ 1							$ 1	[1]
Common stock issued (in shares)	[1]													29,770,563
Common stock issued						$ 126,858								$ 3	[1]							$ 126,855
Common stock issued for conversions of convertible notes (in shares)	[1]										41,063,202
Common stock issued for conversions of convertible notes				$ 187,365							$ 4	[1]								$ 187,361
Stock-based compensation		31,969																	31,969
Net loss		(958,229)																							(958,229)
Other comprehensive income		$ 284																								284
Balance at end of period (in shares) at Dec. 31, 2024		115,639,591	[2]						115,639,591	[1]
Balance at end of period at Dec. 31, 2024		$ 107,422							$ 12	[1]									$ 4,136,586						$ (4,029,298)	$ 122

[1] (1) Amounts have been adjusted to reflect the one-for-thirty (1-for-30) reverse stock split that became effective on June 24, 2024. See Note 1, Basis of Presentation.

[2] Shares issued and outstanding have been adjusted to reflect the one-for-thirty (1-for-30) reverse stock split that became effective on June 24, 2024. See Note 1, Basis of Presentation.